Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis

Please always quote using this URN: urn:nbn:de:bvb:20-opus-226386
  • Allogeneic hematopoietic stem cell transplant remains the only curative treatment for myelofibrosis. Most post-transplantation events Aoccur during the first two years and hence we aimed to analyze the outcome of 2-year disease-free survivors. A total of 1055 patients with myelofibrosis transplanted between 1995 and 2014 and registered in the registry of the European Society for Blood and Marrow Transplantation were included. Survival was compared to the matched general population to determine excess mortality and the risk factors that areAllogeneic hematopoietic stem cell transplant remains the only curative treatment for myelofibrosis. Most post-transplantation events Aoccur during the first two years and hence we aimed to analyze the outcome of 2-year disease-free survivors. A total of 1055 patients with myelofibrosis transplanted between 1995 and 2014 and registered in the registry of the European Society for Blood and Marrow Transplantation were included. Survival was compared to the matched general population to determine excess mortality and the risk factors that are associated. In the 2-year survivors, disease-free survival was 64% (60-68%) and overall survival was 74% (71-78%) at ten years; results were better in younger individuals and in women. Excess mortality was 14% (8-21%) in patients aged <45 years and 33% (13-53%) in patients aged >= 65 years. The main cause of death was relapse of the primary disease. Graft-versus-host disease (GvHD) before two years decreased the risk of relapse. Multivariable analysis of excess mortality showed that age, male sex recipient, secondary myelofibrosis and no GvHD disease prior to the 2-year landmark increased the risk of excess mortality. This is the largest study to date analyzing long-term outcome in patients with myelofibrosis undergoing transplant. Overall it shows a good survival in patients alive and in remission at two years. However, the occurrence of late complications, including late relapses, infectious complications and secondary malignancies, highlights the importance of screening and monitoring of long-term survivors.show moreshow less

Download full text files

Export metadata

Additional Services

Share in Twitter Search Google Scholar Statistics
Metadaten
Author: Marie Robin, Liesbeth C. de Wreede, Christine Wolschke, Johannes Schetelig, Diderik-Jan Eikema, Maria Teresa Van Lint, Nina Simone Knelange, Dietrich Beelen, Arne Brecht, Dietger Niederwieser, Antonin Vitek, Wolfgang Bethge, Renate Arnold, Jürgen Finke, Liisa Volin, Ibrahim Yakoub-Agha, Arnon Nagler, Xavier Poiré, Hermann Einsele, Patrice Chevallier, Ernst Holler, Per Ljungman, Stephen Robinson, Alekxandar Radujkovic, Donal McLornan, Yves Chalandon, Nicolaus Kröger
URN:urn:nbn:de:bvb:20-opus-226386
Document Type:Journal article
Faculties:Medizinische Fakultät / Medizinische Klinik und Poliklinik II
Language:English
Parent Title (English):Haematologica
Year of Completion:2019
Volume:104
Issue:9
Pagenumber:1782-1788
Source:Haematologica 2019 Volume 104(9):1782-1788
DOI:https://doi.org/10.3324/haematol.2018.205211
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
GND Keyword:Midollo-Osseo; LATE DEATHS; Survival; Blood; Ruxolitinib
Tag:European group; Gruppo-italiano; Late mortality; Prognostic scoring system; Societe Francaise
Release Date:2022/09/20
Licence (German):License LogoCC BY-NC: Creative-Commons-Lizenz: Namensnennung, Nicht kommerziell 4.0 International